Stonebridge Capital Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Stonebridge Capital Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$102K	Sell	14,500 -3,000	-17%	-$18.4K	0.01%	213
2026 Q1	$118K	Hold	17,500	–	–	0.01%	209
2025 Q4	$139K	Hold	17,500	–	–	0.01%	210
2025 Q3	$120K	Hold	17,500	–	–	0.01%	213
2025 Q2	$68.3K	Hold	17,500	–	–	0.01%	215
2025 Q1	$66.3K	Hold	17,500	–	–	0.01%	208
2024 Q4	$95K	Hold	17,500	–	–	0.01%	213
2024 Q3	$73.3K	Sell	17,500 -2,500	-13%	-$9.23K	0.01%	221
2024 Q2	$59K	Hold	20,000	–	–	0.01%	215
2024 Q1	$55.4K	Hold	20,000	–	–	0.01%	223
2023 Q4	$56.8K	Hold	20,000	–	–	0.01%	214
2023 Q3	$51.6K	Buy	+20,000	New	+$64.2K	0.01%	357

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Stonebridge Capital Advisors's DMAC Position: Q2 2026 in Review

Stonebridge Capital Advisors reduced its DiaMedica Therapeutics (DMAC) stake by 17% in Q2 2026, selling an estimated $18.4K and leaving 14,500 shares worth $102K. The position accounts for 0.01% of the portfolio, ranked #213.

Stonebridge Capital Advisors first reported a position in DMAC in Q3 2023 and has held it in 12 quarters since. The position peaked at $139K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

Stonebridge Capital Advisors held 14,500 shares of DiaMedica Therapeutics worth $102K as of Q2 2026.
Stonebridge Capital Advisors sold 3,000 DiaMedica Therapeutics shares in Q2 2026, an estimated $18.4K.
DiaMedica Therapeutics made up 0.01% of Stonebridge Capital Advisors's portfolio in Q2 2026, its #213 holding.
Stonebridge Capital Advisors first reported a position in DiaMedica Therapeutics in Q3 2023 and has held it in 12 quarters since.
Stonebridge Capital Advisors's DiaMedica Therapeutics position peaked at $139K in Q4 2025.
89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.